- AdventHealth
Clinical Case Study Published in Gynecologic Oncology Reports
Nathalie D. McKenzie, MD
Nnamdi Gwacham, MD
Gynecologic Oncology Program
AdventHealth Cancer Institute
Nnamdi I. Gwacham1, David Ward2, Nathalie D. McKenzie1
1Gynecologic Oncology Program, AdventHealth Cancer Institute, 2Department of Pathology, AdventHealth Orlando, Orlando, FL 32804
Summary
Primary Langerhans cell histiocytosis (LCH) is very rare and is generally encountered more in the childhood and adolescent populations. Its etiology and pathophysiology as well as reliable modes of therapy remain elusive and variable amongst many institutions. It is characterized by proliferation of dendritic cells derived from myeloid precursors. These cells share immunophenotypic and morphologic characteristics with skin Langerhans cells. The disease carries variable presentation and is rarely encountered in the female reproductive tract. When encountered, the vulva is the most common site affected. We report a case of a 31-year-old woman who presented with isolated LCH of the vulva and clitoris that underwent wide local resection and metastatic workup, including robotic-assisted laparoscopic pelvic lymph node dissection and bone marrow biopsy. Metastatic workup was negative, and she remains without recurrence.
Highlights
- Primary vulvar LCH is rare with less than 40 reported cases.
- Diagnosis of vulvar LCH requires prompt metastatic workup to rule out multi-system involvement.
- Treatment protocols for isolated vulvar LCH vary widely, and there is not an established standard of care.
- Continue surveillance is warranted even after prolonged periods of remission.
For more information or to refer a patient, call GYN Oncology Nurse Navigator Althea Buckner, MSN, APRN-AOCNP, at Call407-303-5909.
Read the Case Study: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8134974/
Recent News
AdventHealth recently began piloting a new Genomics Risk Assessment for Cancer and Early Detection (GRACE) program that combines the use of digital mammography, artificial intelligence (AI) technology...
AdventHealth Clinical Research Unit (CRU) Executive Director and Medical Director of Genitourinary Oncology Guru Sonpavde, MD, co-authored an article on the AMBASSADOR Phase III clinical trial results...
AdventHealth is accelerating the use of research-backed best practices for treating pediatric respiratory infections to combat antibiotic resistance and improve patient outcomes.
AdventHealth Research Institute is currently seeking physicians experiencing exhaustion, irritability, hopelessness, anxiety, work/home imbalance or similar burnout symptoms to participate in a...
A promising new treatment for AFib patients called Pulse Field Ablation is first offered in Central Florida at AdventHealth and shows less damage to tissue.
Plastic and Reconstructive Microsurgeon Sabrina Pavri, MD, and Breast Surgeon Devina McCray, MD, recently began offering immediate neurotization after breast reconstruction, a new surgical technique...
Under the leadership of principal investigator Ki Hyeong Lee, MD, MS, medical director of AdventHealth for Children’s pediatric epilepsy center in Orlando, AdventHealth Orlando has been one of two...
In April 2024, the AdventHealth Neuroscience Institute became the first in Central Florida to treat brain patients with the Elekta Esprit Gamma Knife. This advanced stereotactic radiosurgery (SRS)...
The n-Lorem Foundation recently selected AdventHealth for Children in Orlando as one of the first institutions in Florida to collaborate with providing personalized antisense oligonucleotide (ASO)...
This spring, AdventHealth marked significant advancements in patient care with three “firsts” representing a leap forward in treatment of cardiovascular conditions.
A recent study, called FLOW, showed Ozempic had dramatic results in slowing chronic kidney disease progression in participants with Type 2 diabetes.
With type 1 diabetes on the rise, researchers at AdventHealth are trying to identify undiagnosed type 1 diabetes (T1D) in its early stages, in particular among the state’s underserved and minority...